Xin Lang Cai Jing·2026-02-06 08:36Core Viewpoint - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapies by the Drug Review Center, aimed at treating advanced or metastatic pancreatic cancer with KRASG12D mutations [1] Group 1: Product Development - HRS-4642 is a Class 1 chemical drug developed by the company, intended for first-line treatment of pancreatic cancer with KRASG12D mutations [1] - The drug is expected to be submitted for approval by December 24, 2025 [1] - The total research and development investment for this project has reached approximately 254 million yuan [1] Group 2: Market Context - There are currently no similar drugs approved for market, both domestically and internationally, indicating a potential competitive advantage for the company [1] - The development of the drug is subject to various factors that may introduce uncertainty risks [1]